Risk of relapse in patients receiving azithromycin after allogeneic HSCT.

Kutzke, Jade L; Merten, Julianna A; Taraba, Jodi L; Mara, Kristin C; Shah, Mithun V; Hashmi, Shahrukh K; Patnaik, Mrinal M; Litzow, Mark R; Hogan, William J; Alkhateeb, Hassan B

Kutzke, Jade L; Merten, Julianna A; Taraba, Jodi L; Mara, Kristin C; Shah, Mithun V; Hashmi, Shahrukh K; Patnaik, Mrinal M; Litzow, Mark R; Hogan, William J; Alkhateeb, Hassan B.

Afiliação

Kutzke JL; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. Kutzke.jade@mayo.edu.
Merten JA; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Taraba JL; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Mara KC; Department of Biostatistics, Mayo Clinic, Rochester, MN, USA.
Shah MV; Department of Hematology, Mayo Clinic, Rochester, MN, USA.
Hashmi SK; Department of Hematology, Mayo Clinic, Rochester, MN, USA.
Patnaik MM; Department of Hematology, Mayo Clinic, Rochester, MN, USA.
Litzow MR; Department of Hematology, Mayo Clinic, Rochester, MN, USA.
Hogan WJ; Department of Hematology, Mayo Clinic, Rochester, MN, USA.
Alkhateeb HB; Department of Hematology, Mayo Clinic, Rochester, MN, USA.

Bone Marrow Transplant ; 56(4): 960-962, 2021 04.

Article em En | MEDLINE | ID: mdl-33130820

Assuntos

Azitromicina; Transplante de Células-Tronco Hematopoéticas; Doença Crônica; Humanos; Recidiva; Estudos Retrospectivos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azitromicina / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google